Nova Scotia – Halifax – Halifax
Corporation
www.imvaccine.com
Nova Scotia
Halifax
Halifax
Corporation
active
ImmunoVaccine Technologies Inc (IVT) is a private biotechnology company with facilities in Halifax, Nova Scotia and through acquisition in Doylestown, Pennsylvania. IVT is developing vaccines for human health using two superior technologies which contribute to our pipeline of early stage vaccine products. IVT has developed a lipid depot-based vaccine delivery and enhancement technology called DepoVaxâ„¢, an improvement on IVT€™s original VacciMax® platform. The DepoVaxâ„¢ platform is easy to use, chemically stable, flexible, and forms the basis of IVT€™s therapeutic cancer and single dose infectious disease vaccines. IVT is working towards a pre-clinical package to support single dose DepoVaxâ„¢ platform-based Pandemic Influenza and Hepatitis B vaccines. IVT is also nearing the Pre-IND stage with a DepoVaxâ„¢ platform-based therapeutic cancer vaccine DPX-0907 for breast, ovarian and prostate cancer. With appropriate funding IVT is committed to initiating a Phase 1 clinical trial of a DepoVax(TM) based vaccine in 2009.
Country of Ownership: Canada
Year Established: 2000
Exporting: No
Primary Industry (NAICS): 541710 - Research and Development in the Physical, Engineering and Life Sciences
Alternate Industries (NAICS): 325410 - Pharmaceutical and Medicine Manufacturing
Primary Business Activity: Manufacturer / Processor / Producer
Number of Employees: 18
Products:
Dpx-0907, Single dose pandemic flu vaccine
Technology:
ImmunoVaccine Technologies Inc. (IVT) is a privately held biotechnology company based in Halifax, Nova Scotia, Canada. IVT has developed and patented a proprietary vaccine enhancement platform, VacciMax®, with broad applicability and potential to make a significant contribution to the field of vaccines. Currently, IVT is developing a VacciMax® -based therapeutic vaccine for a cancer application.
VacciMax® is a novel liposome-based product capable of significantly enhancing antibody and cellular immune responses to a variety of antigens with a single dose, including antigens previously considered "poor performers". A single dose of IVT's unique water in oil liposome-based vaccine achieved 100% tumor elimination in three independent pre-clinical cancer models. VacciMax® has also been able to elicit protective levels of antibodies with one dose in a number of pre-clinical human infectious disease models. The safety of VacciMax® has been established in 8 different animal species including cats and monkeys.
IVT has made significant progress in taking VacciMax® from the bench into the clinic. IVT has developed methods to manufacture and characterize VacciMax® and a number of relevant sized batches have been successfully produced at a selected CMO site. IVT's goal is to test a therapeutic cancer vaccine in a Phase I clinical trial in Q4 of 2008. IVT is also looking to provide opportunities for partners to improve their vaccine pipeline by licensing VacciMax® for specific human and animal health vaccines.
Sector:
Key / Major Clients: ImmunoVaccine Technologies Inc. is currently involved in a number of academic and industrial collaborations.
Chase Randal
Korets-Smith Ella
Lowe Brian
No associations
LandOfFree
ImmunoVaccine Technologies Inc. does not yet have a rating. At this time, there are no reviews or comments for this company.
If you have personal experience with ImmunoVaccine Technologies Inc., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ImmunoVaccine Technologies Inc. will most certainly appreciate the feedback.
Profile ID: LFCA-COD-O-31184